Seitkazina, Assel Yang, Jin Kyoung Kim, Sehoon 2024-01-12T02:34:44Z 2024-01-12T02:34:44Z 2022-10-28 2022-12 2508-7940 https://pubs.kist.re.kr/handle/201004/75909 Methylene blue (MB) is a well-known pharmaceutical ingredient that is thought to have a multi-targeted therapeutic effect as an anti-malarial and neuroprotective agent and has recently been identified as a treatment for coronavirus disease 2019 (COVID-19). In this review, we present an overview of relevant clinical trials, including ongoing trials, on the therapeutic uses of MB. A search for clinical trials on clinicaltrials.gov was performed using the terms “methylene blue” and “methylthionine chloride.” This review focuses on clinical trials of MB-based therapies applied to brain diseases, cancer imaging and diagnosis, infectious diseases such as malaria or COVID-19, and cardiovascular diseases. Nanoparticle-based delivery techniques have also been briefly discussed in addition to common delivery methods. English SUNGKYUNKWAN UNIV SCH MEDICINE Clinical effectiveness and prospects of methylene blue: A systematic review Article 10.23838/pfm.2022.00079 1 Precision and Future Medicine, v.6, no.4, pp.193 - 208 Precision and Future Medicine 6 4 193 208 Y